1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT Our speaker is Megan McNiff, a research associate from the John Walton Muscular Dystrophy Research Centre,… Read More »
FSHD University – FSHD Experiences: Insights from Europe
HAT Trick to Block the DUX4 Gene
Researchers Identify a New Compound that Inhibits the Activity of DUX4 By Alec DeSimone, PhD University of Massachusetts Medical School Led by a team at the University of Minnesota, Minneapolis,… Read More »
An undeniable sense of optimism
In this interview, Dr. Jeffery Statland of the University of Kansas Medical Center explains how FSH Society funding seeded the creation of the seven-site Clinical Trial Research Network (CTRN), which… Read More »
Intriguing research on tyrosine kinase inhibition as a potential therapy for FSHD: Sunitinib rescues muscle cells’ ability to develop
Written by Jim Albert Eldersburg, Maryland A cancer drug has been shown to potentially rescue some of the damaging effects of DUX4, the gene implicated in FSH muscular dystrophy…. Read More »
Q &A on potential use of BET inhibitors for FSHD
On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy (FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits bromodomain… Read More »